Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Eloxx Pharmaceuticals Inc
ELOXEloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472
Analytics
Preço Alvo de Wall Street
30 USDRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave ELOX
Análise de Dividendos ELOX
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos ELOX
Avaliação de ações ELOX
Relatório ELOX
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |